A recent study corroborated our findings from another aspect where myeloid-specific IL-6 signaling inhibits liver fibrosis via exosomal transfer of antifibrotic miR-223 into hepatocytes, suggesting the protective role of IL-6 signaling in NAFLD (Hou et al., 2021). This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.